SMT201600289B - Nuove immunoadesine ctla4-ig - Google Patents
Nuove immunoadesine ctla4-igInfo
- Publication number
- SMT201600289B SMT201600289B SM201600289T SM201600289T SMT201600289B SM T201600289 B SMT201600289 B SM T201600289B SM 201600289 T SM201600289 T SM 201600289T SM 201600289 T SM201600289 T SM 201600289T SM T201600289 B SMT201600289 B SM T201600289B
- Authority
- SM
- San Marino
- Prior art keywords
- immunoadesine
- ctla4
- new
- new immunoadesine
- immunoadesine ctla4
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30631110P | 2010-02-19 | 2010-02-19 | |
US33480610P | 2010-05-14 | 2010-05-14 | |
US41230910P | 2010-11-10 | 2010-11-10 | |
PCT/US2011/025747 WO2011103584A2 (en) | 2010-02-19 | 2011-02-22 | Novel ctla4-ig immunoadhesins |
Publications (1)
Publication Number | Publication Date |
---|---|
SMT201600289B true SMT201600289B (it) | 2016-11-10 |
Family
ID=44483626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SM201600289T SMT201600289B (it) | 2010-02-19 | 2016-08-25 | Nuove immunoadesine ctla4-ig |
Country Status (19)
Country | Link |
---|---|
US (7) | US8329867B2 (it) |
EP (2) | EP3053932B1 (it) |
JP (1) | JP5705242B2 (it) |
KR (1) | KR101926663B1 (it) |
CN (3) | CN113372451A (it) |
AU (2) | AU2011217770B2 (it) |
CA (1) | CA2790487C (it) |
CY (2) | CY1118001T1 (it) |
DK (2) | DK2536745T3 (it) |
ES (2) | ES2586579T3 (it) |
HR (2) | HRP20160938T1 (it) |
HU (2) | HUE030100T2 (it) |
LT (2) | LT3053932T (it) |
PL (2) | PL3053932T3 (it) |
PT (1) | PT3053932T (it) |
RS (1) | RS61136B1 (it) |
SI (2) | SI3053932T1 (it) |
SM (1) | SMT201600289B (it) |
WO (1) | WO2011103584A2 (it) |
Families Citing this family (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7094874B2 (en) * | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
IN2014DN10515A (it) | 2006-03-31 | 2015-08-21 | Chugai Pharmaceutical Co Ltd | |
CA2700701C (en) | 2007-09-26 | 2020-12-29 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
SG189775A1 (en) | 2008-04-11 | 2013-05-31 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
US10053513B2 (en) * | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
CA2782218C (en) | 2009-11-30 | 2018-07-31 | Janssen Biotech, Inc. | Antibody fc mutants with ablated effector functions |
HUE030100T2 (en) * | 2010-02-19 | 2017-04-28 | Xencor Inc | New CTLA4-IG immunoadhesins |
CN102822198B (zh) | 2010-03-12 | 2016-08-31 | 艾伯维生物医疗股份有限公司 | Ctla4蛋白和其用途 |
TWI667346B (zh) * | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
CN103328632A (zh) | 2010-11-30 | 2013-09-25 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
SG192945A1 (en) | 2011-02-25 | 2013-09-30 | Chugai Pharmaceutical Co Ltd | Fcgriib-specific fc antibody |
TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
EP3939996A1 (en) | 2011-09-30 | 2022-01-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
RU2739792C1 (ru) | 2011-11-30 | 2020-12-28 | Чугаи Сейяку Кабусики Кайся | Содержащий лекарственное средство переносчик в клетку для формирования иммунного комплекса |
KR101536151B1 (ko) * | 2012-01-31 | 2015-07-14 | 서울대학교산학협력단 | 새로운 CTLA-4IgG 융합 단백질 |
WO2013148049A1 (en) * | 2012-03-29 | 2013-10-03 | The General Hospital Corporation | Recombinant cytotoxic t-lymphocyte-associated protein 4 (ctla4) |
WO2013169338A1 (en) * | 2012-05-11 | 2013-11-14 | Medimmune, Llc | Ctla-4 variants |
WO2013181575A2 (en) | 2012-06-01 | 2013-12-05 | Momenta Pharmaceuticals, Inc. | Methods related to denosumab |
DK2889377T3 (da) | 2012-08-24 | 2020-03-30 | Chugai Pharmaceutical Co Ltd | Fc?RIIb-Specifik Fc-regionsvariant |
US10450361B2 (en) | 2013-03-15 | 2019-10-22 | Momenta Pharmaceuticals, Inc. | Methods related to CTLA4-Fc fusion proteins |
WO2014163101A1 (ja) | 2013-04-02 | 2014-10-09 | 中外製薬株式会社 | Fc領域改変体 |
US10464996B2 (en) | 2013-05-13 | 2019-11-05 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
EP3017048A4 (en) * | 2013-07-01 | 2017-05-17 | University of Maryland, College Park | Fc coupled compositions and methods of their use |
HUE060420T2 (hu) | 2013-09-13 | 2023-02-28 | Beigene Switzerland Gmbh | Anti-PD1 antitestek, valamint terapeutikumként és diagnosztikumként történõ alkalmazásuk |
WO2015057622A1 (en) | 2013-10-16 | 2015-04-23 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
EP3160505A4 (en) | 2014-07-03 | 2018-01-24 | BeiGene, Ltd. | Anti-pd-l1 antibodies and their use as therapeutics and diagnostics |
US10428146B2 (en) | 2014-07-22 | 2019-10-01 | Cb Therapeutics, Inc. | Anti PD-1 antibodies |
JP6909153B2 (ja) | 2014-08-05 | 2021-07-28 | アポロミクス インコーポレイテッド | 抗pd−l1抗体 |
SG10201912591RA (en) | 2014-09-03 | 2020-02-27 | Boehringer Ingelheim Int | Compound targeting il-23a and tnf-alpha and uses thereof |
EP3725808A1 (en) | 2014-11-21 | 2020-10-21 | Bristol-Myers Squibb Company | Antibodies against cd73 and uses thereof |
EA038349B1 (ru) | 2014-11-21 | 2021-08-12 | Бристол-Маерс Сквибб Компани | Антитела, содержащие модифицированные константные участки тяжелой цепи |
BR112017013385A2 (pt) | 2014-12-23 | 2018-02-06 | Bristol-Myers Squibb Company | anticorpos para tigit |
TWI691512B (zh) * | 2015-02-20 | 2020-04-21 | 日商橘生藥品工業股份有限公司 | Fc融合高親和性IgE受體α鏈 |
EP3875477A1 (en) | 2015-04-17 | 2021-09-08 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
KR102138209B1 (ko) | 2015-05-06 | 2020-07-28 | 스니프르 테크놀로지스 리미티드 | 미생물 개체군 변경 및 미생물군 변형 |
FR3035879A1 (fr) * | 2015-05-07 | 2016-11-11 | Lab Francais Du Fractionnement | Mutants fc a activite fonctionnelle modifiee |
UY36687A (es) | 2015-05-29 | 2016-11-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Anticuerpos contra ox40 y sus usos |
JP2018526977A (ja) | 2015-06-29 | 2018-09-20 | ザ ロックフェラー ユニヴァーシティ | アゴニスト活性が増強されたcd40に対する抗体 |
US10280231B2 (en) * | 2015-07-23 | 2019-05-07 | Boehringer Ingelheim International Gmbh | Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof |
SI3370733T1 (sl) | 2015-11-02 | 2021-11-30 | Board Of Regents The University Of Texas System | Postopek za aktivacijo CD40 in blokada imunske nadzorne točke |
AU2016349632A1 (en) | 2015-11-07 | 2018-05-24 | Multivir Inc. | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
EP3192805A1 (en) * | 2016-01-15 | 2017-07-19 | Humanitas Mirasole S.p.A. | Inhibitors of t cell activation or stimulation and uses thereof |
EA201891983A8 (ru) | 2016-03-04 | 2020-05-28 | Бристол-Майерс Сквибб Компани | Комбинированная терапия антителами к cd73 |
EP3423489A1 (en) | 2016-03-04 | 2019-01-09 | The Rockefeller University | Antibodies to cd40 with enhanced agonist activity |
WO2017160599A1 (en) | 2016-03-14 | 2017-09-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of cd300b antagonists to treat sepsis and septic shock |
US11046782B2 (en) | 2016-03-30 | 2021-06-29 | Musc Foundation For Research Development | Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination |
JP7131773B2 (ja) | 2016-04-29 | 2022-09-06 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | ホルモン受容体に関連する転写活性の標的尺度 |
GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
JP6993056B2 (ja) | 2016-07-05 | 2022-02-15 | ベイジーン リミテッド | 癌治療のためのpd-1アンタゴニスト及びraf阻害剤の組合せ |
AU2017313085A1 (en) | 2016-08-19 | 2019-03-14 | Beigene Switzerland Gmbh | Use of a combination comprising a Btk inhibitor for treating cancers |
BR112019006041A2 (pt) | 2016-09-27 | 2019-09-03 | Univ Texas | métodos para aprimorar a terapia de bloqueio do ponto de verificação imunológico por modulação do microbioma |
JP7041136B2 (ja) | 2016-10-12 | 2022-03-23 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | Tusc2免疫療法のための方法および組成物 |
US11883430B2 (en) | 2016-11-09 | 2024-01-30 | Musc Foundation For Research Development | CD38-NAD+ regulated metabolic axis in anti-tumor immunotherapy |
CN110381997A (zh) | 2016-12-12 | 2019-10-25 | 茂体外尔公司 | 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物 |
EP3573989A4 (en) | 2017-01-25 | 2020-11-18 | Beigene, Ltd. | CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) -PIPERIDINE-4-YL) -2- (4-PHENOXYPHENYL) -4,5,6,7-TETRAHYDROPYRAZOLO [1,5-A ] PYRIMIDINE-3-CARBOXAMIDE, MANUFACTURING AND USES THEREOF |
JP7162398B2 (ja) | 2017-02-24 | 2022-10-28 | ボード オブ リージェンツ ザ ユニヴァーシティ オブ テキサス システム | 早期膵がん検出アッセイ |
BR112019018747A2 (pt) * | 2017-03-16 | 2020-05-05 | Alpine Immune Sciences Inc | proteínas imunomoduladoras variantes de cd80 e usos das mesmas |
TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
EP3620531A4 (en) | 2017-05-02 | 2021-03-17 | National Center of Neurology and Psychiatry | METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS |
CN110719915A (zh) | 2017-05-25 | 2020-01-21 | 百时美施贵宝公司 | 包含经修饰的重链恒定区的抗体 |
KR20200015717A (ko) | 2017-06-09 | 2020-02-12 | 프로비던스 헬스 앤드 서비시즈 - 오레곤 | 암 치료를 위한 인간 종양 반응성 t 세포의 확인을 위한 cd39 및 cd103의 활용 |
US11597768B2 (en) | 2017-06-26 | 2023-03-07 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
EP3587445B1 (en) * | 2017-08-10 | 2023-12-13 | Grifols Diagnostic Solutions Inc. | An oligomerization tag comprising an immunoglobulin fc region and a polyhis domain |
US11753458B2 (en) * | 2017-10-10 | 2023-09-12 | Alpine Immune Sciences, Inc. | CTLA-4 variant immunomodulatory proteins and uses thereof |
CN111712515A (zh) | 2017-10-18 | 2020-09-25 | 高山免疫科学股份有限公司 | 变体icos配体免疫调节蛋白及相关组合物和方法 |
CN111801334B (zh) | 2017-11-29 | 2023-06-09 | 百济神州瑞士有限责任公司 | 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤 |
CN111788227A (zh) | 2017-12-27 | 2020-10-16 | 百时美施贵宝公司 | 抗cd40抗体及其用途 |
EP3762023A4 (en) * | 2018-03-05 | 2021-12-29 | New York University | Induction and enhancement of antitumor immunity involving sindbis virus vectors expressing immune checkpoint proteins |
JP2021518408A (ja) | 2018-03-19 | 2021-08-02 | マルチビア インコーポレイテッド | 癌治療のための、癌抑制遺伝子治療法及びcd122/cd132アゴニストを含む、方法及び組成物 |
WO2019185551A1 (en) | 2018-03-25 | 2019-10-03 | Snipr Biome Aps. | Treating & preventing microbial infections |
US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
BR112020023860A2 (pt) * | 2018-05-25 | 2021-04-13 | Dr. Reddy's Laboratories Ltd. | Formulação estável de proteína de fusão, e, métodos para obter uma formulação estável e para aumentar a estabilidade de proteína de fusão |
KR20210124179A (ko) * | 2018-11-02 | 2021-10-14 | 베이징 브이디제이바이오 컴퍼니 리미티드 | 변형된 ctla4 및 이의 사용 방법 |
CN113286813A (zh) | 2018-11-19 | 2021-08-20 | 得克萨斯大学体系董事会 | 用于car和tcr转导的模块化多顺反子载体 |
CN113348177A (zh) | 2018-11-28 | 2021-09-03 | 百时美施贵宝公司 | 包含经修饰的重链恒定区的抗体 |
CN113272427A (zh) | 2018-11-28 | 2021-08-17 | 得克萨斯大学体系董事会 | 免疫细胞的多重基因组编辑以增强功能性和对抑制环境的抵抗力 |
KR20210096648A (ko) | 2018-11-29 | 2021-08-05 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 자연 살해 세포의 생체외 확장을 위한 방법 및 이의 용도 |
AU2020268199A1 (en) | 2019-05-09 | 2021-11-18 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of hepatocytes |
TW202110431A (zh) | 2019-05-17 | 2021-03-16 | 美商癌症預防製藥股份有限公司 | 治療家族性腺瘤性瘜肉症之方法 |
AU2020300002A1 (en) | 2019-07-01 | 2022-02-24 | Tonix Pharma Limited | Anti-CD154 antibodies and uses thereof |
KR20220066276A (ko) * | 2019-08-22 | 2022-05-24 | 시다라 세라퓨틱스, 인코포레이티드 | 변이체 fc 도메인 및 이의 용도 |
WO2021087458A2 (en) | 2019-11-02 | 2021-05-06 | Board Of Regents, The University Of Texas System | Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer |
WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
EP4087922A4 (en) | 2020-01-07 | 2024-01-10 | Univ Texas | HUMAN ADENOSINE/METHYLTHIOADENOSINE DEPLETING ENZYME VARIANTS FOR CANCER TREATMENT |
AU2021205337A1 (en) | 2020-01-10 | 2022-07-21 | Modernatx, Inc. | Methods of making tolerogenic dendritic cells |
EP4096720A2 (en) | 2020-01-30 | 2022-12-07 | ModernaTX, Inc. | Mrnas encoding metabolic reprogramming polypeptides and uses thereof |
CA3168337A1 (en) | 2020-02-17 | 2021-08-26 | Marie-Andree Forget | Methods for expansion of tumor infiltrating lymphocytes and use thereof |
WO2021231732A1 (en) | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
JP2023526416A (ja) | 2020-05-21 | 2023-06-21 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | Vgll1特異性を有するt細胞受容体およびその使用法 |
WO2021247836A1 (en) | 2020-06-03 | 2021-12-09 | Board Of Regents, The University Of Texas System | Methods for targeting shp-2 to overcome resistance |
CA3201499A1 (en) | 2020-11-13 | 2022-05-19 | Catamaran Bio, Inc. | Genetically modified natural killer cells and methods of use thereof |
EP4251645A1 (en) | 2020-11-25 | 2023-10-04 | Catamaran Bio, Inc. | Cellular therapeutics engineered with signal modulators and methods of use thereof |
JP2024503625A (ja) | 2021-01-06 | 2024-01-26 | トニックス ファーマ リミテッド | 改変された抗cd154抗体により免疫寛容を誘導する方法 |
CN117529338A (zh) | 2021-01-19 | 2024-02-06 | 威廉马歇莱思大学 | 多肽的骨特异性递送 |
BR112023022097A2 (pt) | 2021-06-07 | 2023-12-19 | Agonox Inc | Cxcr5, pd-1 e icos expressando células t cd4 reativas de tumor e seu uso |
IL309208A (en) | 2021-06-11 | 2024-02-01 | Sage Therapeutics Inc | Neuroactive steroids for the treatment of Alzheimer's disease |
AU2022324040A1 (en) | 2021-08-04 | 2024-02-22 | The Regents Of The University Of Colorado, A Body Corporate | Lat activating chimeric antigen receptor t cells and methods of use thereof |
CA3234457A1 (en) | 2021-10-05 | 2023-04-13 | Cytovia Therapeutics, Llc | Natural killer cells and methods of use thereof |
TW202330612A (zh) | 2021-10-20 | 2023-08-01 | 日商武田藥品工業股份有限公司 | 靶向bcma之組合物及其使用方法 |
WO2023076880A1 (en) | 2021-10-25 | 2023-05-04 | Board Of Regents, The University Of Texas System | Foxo1-targeted therapy for the treatment of cancer |
WO2023070160A1 (en) * | 2021-10-28 | 2023-05-04 | Monash University | Variant ctla4 proteins |
WO2023112000A2 (en) * | 2021-12-17 | 2023-06-22 | Kashiv Biosciences, Llc | An improved method for separation of low molecular weight proteins |
WO2023211972A1 (en) | 2022-04-28 | 2023-11-02 | Medical University Of South Carolina | Chimeric antigen receptor modified regulatory t cells for treating cancer |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK287940B6 (sk) * | 2000-07-03 | 2012-05-03 | Bristol-Myers Squibb Company | Soluble CTLA4 fusion molecule, pharmaceutical composition comprising thereof and its use |
WO2002058729A2 (en) * | 2001-01-26 | 2002-08-01 | Emory University | Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
CN1443850A (zh) * | 2002-03-08 | 2003-09-24 | 重庆立丹(集团)药业科技开发有限公司 | 重组人ctla4胞外区蛋白的制备方法及其所得产品和用途 |
US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
US20060134105A1 (en) | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
CN101519451B (zh) * | 2005-04-05 | 2011-05-25 | 上海中信国健药业股份有限公司 | 重组人sCTLA4-Ig融合蛋白基因及其药物组合物 |
GB0620934D0 (en) | 2006-10-20 | 2006-11-29 | Cambridge Antibody Tech | Protein variants |
EP2176298B1 (en) | 2007-05-30 | 2017-11-15 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
PT2222697E (pt) * | 2007-11-01 | 2013-02-15 | Perseid Therapeutics Llc | Polipeptídeos imunossupressores e ácidos nucleicos |
EP4098661A1 (en) * | 2007-12-26 | 2022-12-07 | Xencor, Inc. | Fc variants with altered binding to fcrn |
ES2458541T3 (es) | 2008-05-02 | 2014-05-06 | Seattle Genetics, Inc. | Métodos y composiciones para elaborar anticuerpos y derivados de anticuerpos con fucosilación del núcleo reducida |
HUE030100T2 (en) * | 2010-02-19 | 2017-04-28 | Xencor Inc | New CTLA4-IG immunoadhesins |
CN102822198B (zh) * | 2010-03-12 | 2016-08-31 | 艾伯维生物医疗股份有限公司 | Ctla4蛋白和其用途 |
-
2011
- 2011-02-22 HU HUE11727563A patent/HUE030100T2/en unknown
- 2011-02-22 SI SI201131924T patent/SI3053932T1/sl unknown
- 2011-02-22 JP JP2012554096A patent/JP5705242B2/ja active Active
- 2011-02-22 SI SI201130917A patent/SI2536745T1/sl unknown
- 2011-02-22 RS RS20201231A patent/RS61136B1/sr unknown
- 2011-02-22 PT PT151985165T patent/PT3053932T/pt unknown
- 2011-02-22 LT LTEP15198516.5T patent/LT3053932T/lt unknown
- 2011-02-22 ES ES11727563.6T patent/ES2586579T3/es active Active
- 2011-02-22 CA CA2790487A patent/CA2790487C/en active Active
- 2011-02-22 PL PL15198516T patent/PL3053932T3/pl unknown
- 2011-02-22 LT LTEP11727563.6T patent/LT2536745T/lt unknown
- 2011-02-22 DK DK11727563.6T patent/DK2536745T3/en active
- 2011-02-22 EP EP15198516.5A patent/EP3053932B1/en active Active
- 2011-02-22 ES ES15198516T patent/ES2826894T3/es active Active
- 2011-02-22 CN CN202110326502.3A patent/CN113372451A/zh active Pending
- 2011-02-22 WO PCT/US2011/025747 patent/WO2011103584A2/en active Application Filing
- 2011-02-22 KR KR1020127024362A patent/KR101926663B1/ko active IP Right Grant
- 2011-02-22 PL PL11727563T patent/PL2536745T3/pl unknown
- 2011-02-22 EP EP11727563.6A patent/EP2536745B1/en active Active
- 2011-02-22 US US13/032,491 patent/US8329867B2/en active Active
- 2011-02-22 AU AU2011217770A patent/AU2011217770B2/en active Active
- 2011-02-22 DK DK15198516.5T patent/DK3053932T3/da active
- 2011-02-22 HU HUE15198516A patent/HUE050768T2/hu unknown
- 2011-02-22 CN CN201610569505.9A patent/CN106432473B/zh active Active
- 2011-02-22 CN CN201180019721.1A patent/CN103038251B/zh active Active
-
2012
- 2012-12-10 US US13/710,305 patent/US8629113B2/en active Active
-
2013
- 2013-12-27 US US14/142,705 patent/US9371397B2/en active Active
-
2016
- 2016-05-03 AU AU2016202816A patent/AU2016202816B2/en active Active
- 2016-05-19 US US15/159,667 patent/US10155800B2/en active Active
- 2016-07-25 HR HRP20160938TT patent/HRP20160938T1/hr unknown
- 2016-08-10 CY CY20161100794T patent/CY1118001T1/el unknown
- 2016-08-25 SM SM201600289T patent/SMT201600289B/it unknown
-
2018
- 2018-11-13 US US16/189,917 patent/US11352412B2/en active Active
-
2020
- 2020-10-08 HR HRP20201614TT patent/HRP20201614T1/hr unknown
- 2020-10-20 CY CY20201100987T patent/CY1124024T1/el unknown
-
2021
- 2021-04-15 US US17/231,848 patent/US11254727B2/en active Active
-
2022
- 2022-05-04 US US17/736,917 patent/US20220348634A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SMT201600289B (it) | Nuove immunoadesine ctla4-ig | |
BR112012028556A2 (pt) | Indóis | |
DE102011100241A8 (de) | Nitridhalbleiterbauteil | |
DK3225404T3 (da) | Fluidpatron | |
CR20130111A (es) | Triazina-oxidiazoles | |
DE10170954T8 (de) | Mikrowellendruckgarer | |
DE112011104226A5 (de) | Käfigmutter | |
DE102011117046A8 (de) | Doppelkupplungswindungsgetriebe | |
DE112011101226A5 (de) | Linearwegmesssystem | |
DE112011102080A5 (de) | Kupplungszentralausrücker | |
DK2442899T3 (da) | Rotorskive | |
DK2539163T3 (da) | Dækventil | |
DE102011002623A8 (de) | Ventilsteuerzeitversteller | |
DE112011102711A5 (de) | Hydrostataktor | |
DK2448659T3 (da) | Rotorskive | |
DK2447426T3 (da) | Vaske-WC | |
DE102010019119B8 (de) | Cuttermesser | |
DE102010038420A8 (de) | Reinigungungsvorrichtung | |
DK2596072T3 (da) | Bor-forbindelses-suspension | |
DK2521486T3 (da) | Palpometer | |
DE112010005518A5 (de) | Dichtungsmanchette | |
CO6801789A2 (es) | N-hetarilmetil pirazolilcarboxamidas | |
DE112011101796A5 (de) | Redoxakkumulatoranlage | |
DE102010035554B8 (de) | Fußtüröffner | |
DK2404809T3 (da) | Trækbjælke |